The heart of this deal is AJ1-11095, an oral drug from Ajax that is still in early testing but shows promise for patients who have not had much luck with other treatments.
Eli Lilly wants to share clinical results by 2026 and speed things up from there.
Lilly says they are excited about bringing something important to people fighting blood cancer.